Description: ARN21934 is a Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over beta. It has an IC50 of 2 μM for inhibition of DNA relaxation, as compared to an IC50 of 120 μM for the anticancer drug etoposide] with excellent metabolic stability and solubility. ARN21934 also shows ~100-fold selectivity for topoIIα over topobeta, a broad antiproliferative activity toward cultured human cancer cells, a favorable in vivo pharmacokinetic profile, and the ability to penetrate the blood–brain barrier. Thus, ARN-21934 is a highly promising lead for the development of novel and potentially safer topoII-targeted anticancer drugs.

纯度：≥98%